Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173
Phase of Trial: Phase I
Latest Information Update: 31 May 2016
Price : $35 *
At a glance
- Drugs Veldoreotide (Primary) ; Octreotide
- Indications Acromegaly
- Focus Pharmacodynamics
- Sponsors Aspireo Pharmaceuticals
- 31 May 2016 According to a Strongbridge Biopharma media release, data from this study were presented at the 18th European Congress of Endocrinology.
- 30 Apr 2014 New trial record
- 22 Apr 2014 Results reported in an Aspireo Pharmaceuticals media release.